TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03506074

Intervention type: DIAGNOSTIC_TEST
Intervention: Flavor test
Description: The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
Study: NCT02893839

Intervention type: OTHER
Group type: OTHER
Intervention: Prick to prick test
Study: NCT01800890

Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast A
Description: Coloplast A is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast A
Description: Coloplast A is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast B
Description: Coloplast B is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast B
Description: Coloplast B is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast C
Description: Coloplast C is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast C
Description: Coloplast C is a newly developed 2-piece ostomy appliance

Intervention type: DEVICE
Group type: OTHER
Intervention: SenSura Click
Description: The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
Study: NCT03221998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV paracetamol
Description: 100 gram paracetamol infusion for moderate pain management

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV saline (NaCl 0.9 %)
Description: 100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
Study: NCT01800890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Click
Description: The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Click
Description: The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
Study: NCT00630734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 1-4
Study: NCT02589080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-invasive sensory feedback
Description: A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback.
Study: NCT00988000

Intervention type: OTHER
Group type: OTHER
Intervention: telephone consultation
Description: alternative to face to face consultation for new referrals

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: no alternative to face to face consultation

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: no alternative to face to face consultation
Study: NCT04263246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoDyNAmic
Description: PhytoDyNAmic (6 capsules per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: Inulin (6 capsules per day)
Study: NCT03131115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Crural Strut Graft
Description: surgical technique as described

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Anchored Suspension
Description: Surgical technique as described
Study: NCT00630734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600mg by mouth twice daily on days 12-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600mg by mouth twice daily on days 12-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600mg by mouth twice daily on days 12-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg by mouth twice daily on days 12-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg by mouth twice daily on days 12-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg by mouth twice daily on days 12-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 15-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 15-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40 mg by mouth daily on days 15-18

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: Washout (no medication) on days 5-11.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: Washout (no medication) on days 5-11.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: Washout (no medication) on days 5-11.
Study: NCT04536129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (CORTIVIS ®)
Description: Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone (CORTIVIS ®)
Description: Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
Study: NCT01735227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
Study: NCT04168983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sophrology
Description: Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
Study: NCT05216822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
Study: NCT02489968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg + linagliptin 5 mg
Description: empagliflozin low dose + linagliptin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Description: empagliflozin low dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg + linagliptin 5 mg
Description: empagliflozin high dose + linagliptin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Description: empagliflozin high dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00507403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Study: NCT01214642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously
Study: NCT00724165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Culturally-modified, individually tailored physical activity print materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Bilingual health education booklets
Study: NCT04822077

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: * Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)
Study: NCT03993262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
Study: NCT03028675

Intervention type: OTHER
Intervention: MRI Scan
Description: MRI scans will consist of a 1-hour brain scan for both patients and controls.

Intervention type: OTHER
Intervention: MRI Scan
Description: MRI scans will consist of a 1-hour brain scan for both patients and controls.
Study: NCT00766597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
Study: NCT03166020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: An occupational therapist will be required only for patient installation in front of the table.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: An occupational therapist will be required only for patient installation in front of the table.
Study: NCT02565602

Intervention type: OTHER
Group type: OTHER
Intervention: Ca-41(isotope tracer)
Description: Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.

Intervention type: OTHER
Group type: OTHER
Intervention: Sr-84 (isotope tracer)
Description: Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: One tablet daily (400IU per tablet)
Study: NCT03560011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunoglobulin IV
Description: 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
Study: NCT03318003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-PAP
Description: Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
Study: NCT01968811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Foam dressing kit
Study: NCT04190862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Injection of E-CEL UVEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Injection of E-CEL UVEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Injection of E-CEL UVEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Injection of E-CEL UVEC
Study: NCT03118817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573
Description: Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops
Study: NCT01241708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.6mg/m2 on day -4 and day -1
Study: NCT01535313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OnControl BM-Biopsy system
Description: Bone marrow biopsy at posterior iliac crest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnControl BM-Biopsy system
Description: Bone marrow biopsy at posterior iliac crest
Study: NCT00509899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
Study: NCT01854697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alpha 2-a (PegIFN)
Description: Pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alpha 2-a (PegIFN)
Description: Pre-filled syringe
Study: NCT03445000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose.
Study: NCT00715299

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: locomotor training
Description: Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
Study: NCT02824146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver
Description: The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
Study: NCT02274597

Intervention type: DEVICE
Intervention: metraux epitympanic thermometer
Description: accuracy of epitympanic temperature measurement in different environmental settings
Study: NCT04473872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory rehabilitation
Description: intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory rehabilitation
Description: intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory rehabilitation
Description: intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
Study: NCT02326272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use
Study: NCT04009304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSNAP
Description: Afterschool practice and policy change to support healthy eating and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSNAP
Description: Afterschool practice and policy change to support healthy eating and physical activity
Study: NCT01870986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: 40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab-EU)
Description: 40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira (adalimumab-US)
Description: 40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
Study: NCT03038529

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic postrolateral extraarticular percutaneous approach for O3 injection
Description: Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postrolateral transforaminal approach (Yess approach ) for O3 injection
Description: Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
Study: NCT01050946

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haploidentical/cord transplant
Description: Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion